Despite Advances in Hepatitis C Treatment, More Research Needed (Video)

On behalf of IFARA, Liz Highleyman, editor-in-chief of, spoke with Jurgen Rockstroh, M.D., Kenneth Sherman, M.D., Ph.D., and Dost Sarpel, M.D., about research on the treatment of hepatitis B and C. One trial found that a six-week course of ledipasvir and sofosbuvir (Harvoni) cleared acute hepatitis C (HCV) in most patients, except for those with very high viral loads. Another study showed that a new HIV drug, cenicriviroc, can inhibit the hepatic fibrosis often experienced by people living with HIV. Risk factors for HCV treatment failure were the focus of a third study. HCV reinfection, as well as a higher risk for developing liver cancer after being cured of this virus, are other areas of concern, as is the need for drugs to re-treat those for whom HCV treatment did not work the first time around.

Watch the video to learn more:

About the panelists:

  • Jürgen Rockstroh, M.D., University of Bonn, Germany
  • Dost Sarpel, M.D., Icahn School of Medicine at Mount Sinai, New York, N.Y.
  • Kenneth Sherman, M.D., Ph.D., University of Cincinnati, Ohio

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.